Blueprint Medicines' Series A - II Round

Blueprint Medicines raised a round of funding on May 24, 2012.

Blueprint Medicines is a patient-driven oncology company discovering and developing highly selective kinase inhibitors for genomically defined cancers. Led by a management team and advisors with world…

Articles about Blueprint Medicines' Series A - II Round: